Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86Y78

UPID:
LYPD6_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q86Y78; B3KWC0; Q4G121; Q53TR3; Q659B1

BACKGROUND:
The Ly6/PLAUR domain-containing protein 6 is identified as a modulator of nicotinic acetylcholine receptors, which are key players in synaptic transmission in the brain. By inhibiting nicotine-induced calcium influx, it impacts neuronal activity and signaling. Its specific inhibition of alpha-3:beta-4 and alpha-7 nAChR currents highlights its potential as a target for modulating brain function. Furthermore, its role in enhancing Wnt/beta-catenin signaling pathways underscores its importance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Ly6/PLAUR domain-containing protein 6 offers promising avenues for the development of novel therapeutic interventions, especially for conditions related to impaired nAChR activity or abnormal Wnt/beta-catenin signaling.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.